This incomplete epistasis – the observation that even fully ablated PARylation activity only modestly impairs TMEJ activity – helps explain why the toxicity of PARPi and Polθi is additive in HR-deficient cancers, and better rationalizes the utility of combined therapy. The gene discussed is POLI; the disease is cancer.